source
- Adaptyv Bio shares results from its latest AI-driven protein design contestAdaptyv Bio, a biotech firm focused on protein engineering, released the outcomes of its newest competition that tests how well artificial‑intelligence models can create novel proteins. The challe…
- Intellia’s CRISPR therapy cuts hereditary angioedema attacks by 87% in Phase 3 trialIntellia Therapeutics reported that its experimental CRISPR-based drug lonvo-z met the primary endpoint in a Phase 3 study for hereditary angioedema, a rare swelling disorder. The trial showed an…